At ART BioScience we are committed to the development of a new class of therapeutics based on messenger RNA (mRNA) for the treatment of Orphan diseases, primarily Duchenne Muscular Dystrophy
To be recognized as a leader in the discovery, development and commercialization of novel mRNA therapeutics by leveraging a deep understanding of Duchenne biology, specifically strengthening the musculoskeletal system.
Our leadership team has deep and diverse industry knowledge, a passion for science and innovation, and we consistently push the boundaries of scientific excellence and discovery in order to transform lives.
